Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/ap/2012-11-13/astrazeneca-german-court-voids-seroquel-xr-patent

AP News

AstraZeneca: German court voids Seroquel XR patent


NEW YORK (AP) — AstraZeneca PLC said Tuesday a German court threw out a patent protecting its antipsychotics drug Seroquel XR.

The British drugmaker said the patent was being challenged by several companies, including the German unit of Teva Pharmaceutical Industries Ltd.

Seroquel XR is one of the company's top-selling drugs, as worldwide sales grew 7 percent to $1.13 billion over the first nine months of 2012. The U.S. patents protecting Seroquel XR are set to expire in late 2017, and AstraZeneca agreed to allow Intellipharmaceutics to sell an authorized generic version starting in November 2016. Other drug companies are also seeking approval to market generic versions of the drug.

U.S.-listed shares of AstraZeneca rose 15 cents to $45.46 on Tuesday.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus